Abstract:ETHNOPHARMACOLOGICAL RELEVANCE: Ganoderma lucidum (G. lucidum) was regarded as "miraculous herb" by the Chinese and recorded detailly in the "Shen Nong Ben Cao Jing" as a tonic to improve health and prolong life. A proteoglycan (namely, FYGL) was extracted from Ganoderma lucidum, which was a water-soluble hyperbranched proteoglycan, and was found to be able to protect pancreatic tissue against oxidative stress damage.AIM OF THE STUDY: Diabetic kidney disease (DKD) is a complication of diabetes, but the effective treatment is still lack. Chronic hyperglycemia in diabetic patients induce the accumulation of ROS, which injure the renal tissue and lead to the renal dysfunction. In this work, the efficacy and target mechanics of FYGL on diabetic renal function were investigated.MATERIALS AND METHODS: In the present study, the mechanism of the reno-protection of FYGL was analyzed on diabetic db/db mice and rat glomerular mesangial cells (HBZY-1) induced by high glucose (HG) with palmitate (PA) (HG/PA). In vitro, the levels of reactive oxygen species (ROS), malondialdehyde (MDA) and superoxide dismutase (SOD) were evaluated by commercial kits. the expressions of NOX1 and NOX4, phosphorylation of MAPK and NF-κB, and pro-fibrotic proteins were measured by Western blot. In vivo, diabetic db/db mice were gavaged with FYGL for 8 weeks, body weight and fasting blood glucose (FBG) were tested weekly. On 8th week, the serum, urine and renal tissue were collected for glucose tolerance test (OGTT), redox indicator (SOD, CAT, GSH and MDA), lipid metabolism (TC, TG, LDL and HDL), blood urea nitrogen (BUN), serum creatinine (Scr), uric acid (UA), 8-oxo-deoxyguanosine (8-OHdG), and the changes of histopathology and expression of collagen IV and AGEs.RESULTS: The results in vitro showed that FYGL significantly inhibited the HG/PA-induced HBZY-1 cells proliferation, ROS generation, MDA production, promoted SOD activity, and suppressed NOX1, NOX4, MAPK, NF-κB, and pro-fibrotic proteins expression. In addition, FYGL markedly alleviated blood glucose, antioxidant activity and lipid metabolism, improved renal functions, and relieved renal histopathological abnormalities, especially renal fibrosis.CONCLUSIONS: The antioxidant activity of FYGL can reduce ROS caused by diabetes and protect renal from oxidative stress-induced dysfunction, thereby improving renal function. This study shows that FYGL has the potential to treat diabetic kidney disease.

Inhibition on α-Glucosidase Activity and Non-Enzymatic Glycation by an Anti-Oxidative Proteoglycan from Ganoderma lucidum

Antidiabetic, Antihyperlipidemic and Antioxidant Activities of a Novel Proteoglycan from Ganoderma Lucidum Fruiting Bodies on Db/db Mice and the Possible Mechanism.

A proteoglycan isolated from Ganoderma lucidum attenuates diabetic kidney disease by inhibiting oxidative stress-induced renal fibrosis both in vitro and in vivo

Hypoglycemic Mechanism of a Novel Proteoglycan, Extracted from Ganoderma Lucidum, in Hepatocytes

Antioxidation of a proteoglycan from Ganoderma lucidum protects pancreatic β-cells against oxidative stress-induced apoptosis in vitro and in vivo

Effects of a Ganoderma lucidum Proteoglycan on Type 2 Diabetic Rats and the Recovery of Rat Pancreatic Islets

Structural Characterization and Bioactivity Evaluation of an Acidic Proteoglycan Extract from Ganoderma Lucidum Fruiting Bodies for PTP1B Inhibition and Anti-Diabetes.

Effects of a<i> Ganoderma</i><i> lucidum</i> Proteoglycan on Type 2 Diabetic Rats and the Recovery of Rat Pancreatic Islets

Ganoderma Lucidum Polysaccharides Exert Anti-Hyperglycemic Effect On Streptozotocin-Induced Diabetic Rats Through Affecting Beta-Cells

Isolation and Characterization of a Hyperbranched Proteoglycan from Ganoderma Lucidum for Anti-Diabetes

A Proteoglycan Extract Fromganoderma Lucidumprotects Pancreatic Beta-Cells Against STZ-induced Apoptosis

Effect of a Novel Proteoglycan PTP1B Inhibitor from Ganoderma Lucidum on the Amelioration of Hyperglycaemia and Dyslipidaemia in Db/db Mice.

Biodistribution and Immunomodulatory Activities of a Proteoglycan Isolated from Ganoderma Lucidum

Balancing adipocyte production and lipid metabolism to treat obesity-induced diabetes with a novel proteoglycan from Ganoderma lucidum

A Novel Proteoglycan from Ganoderma Lucidum Fruiting Bodies Protects Kidney Function and Ameliorates Diabetic Nephropathy Via Its Antioxidant Activity in C57bl/6 Db/Db Mice

A natural hyperbranched proteoglycan inhibits IAPP amyloid fibrillation and attenuates beta-cell apoptosis

The thermodynamic and kinetic mechanisms of a<i> Ganoderma</i><i> lucidum</i> proteoglycan inhibiting hIAPP amyloidosis

Modulation of energy metabolism and mitochondrial biogenesis by a novel proteoglycan from Ganoderma lucidum

Interaction and Inhibition of a Ganoderma Lucidum Proteoglycan on PTP1B Activity for Anti-diabetes.

A protein tyrosine phosphatase 1B activity inhibitor from the fruiting bodies of Ganoderma lucidum (Fr.) Karst and its hypoglycemic potency on streptozotocin-induced type 2 diabetic mice.

The inhibition of oleanolic acid on protein non-enzymatic glycation